Related Experiment Video
Updated: Aug 17, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Oxamniquine pharmacokinetics in healthy Kenyan African volunteers
1Department of Pharmacy, University of Nairobi, Kenya.
Abstract:
Oxamniquine pharmacokinetics were studied following oral administration of 750, 1000 mg or 1250 mg (equivalent to approximately 15 mg/kg) to five healthy Kenyan African volunteers. Peak plasma concentrations ranging between 1 and 4.3 mg/1 were achieved 1 to 4 h after dosing. The estimated mean elimination half-life (t1/2) was 2.2 h. Despite the limited number of subjects in the study, it is concluded that the pharmacokinetics of oxamniquine in healthy Kenyan Africans do not markedly differ from those in Africans from other regions of the continent where previous studies have been reported.
Related Concept Videos
Cholinergic Antagonists: Pharmacokinetics
Bioavailability Study Design: Healthy Subjects Versus Patients
Dosage Regimens: Partial Pharmacokinetic Parameters
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Pharmacokinetics in Pediatric Patients: Drug Excretion

